Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (23)	1/16/1999 9:27:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 423

Hi yosi, I invest in all sorts of biotechs. Yes many with novel therapeutic potential. I don't disagree with your investment or investing style as you call it. I am not against novel therapeutics. As far as potential goes each stock is evaluated based on it's own merits. I invest in NTII because of it's product potential and reduced risk. I am not looking to compair stocks or investing philosophies. The purpose of this thread is to isolate those stocks which are out of favior and significantly undervalued ( on a relative basis ) based on future expectations. If you have reason to believe this is true about PARS please continue to give us updates on your pick. See Yosi many of us follow 10's or even 100's of stocks. My goal is to get willing contributors to commit to one or two stocks which they believe will move significantly ( at least 100% ) over say a six month period and to state the reasons to anticipate higher values. I believe NTII can realistically trade to above $2 on a sustained basis once it completes it's collaboration with a Big Pharma. That will be 300% returns from the .50 cent potential entry point from when I started this thread. BEST WISHES Jeffrey